Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer
Open-label, Multicenter,PhaseI Trial in Order To Determine the Safety and Pharmacokinetics of BAY43-9006 in Combination With Docetaxel as First-line Treatment in Metastatic Hormone Refractory Prostate Cancer Patients
The purpose of the trial is to determine the most effective dose of BAy 46-9003 associated to taxotere for first-line treatment of patient with prostatic cancer.
BAY 43-9006 (SORAFENIB) is a novel dual-action Raf kinase and VEGFR inhibitor, which is orally available and has a favorable safety profile in patients with advanced solid tumors. This, together with the antitumor activity observed after treatment with BAY 43-9006 (SORAFENIB), provides a rationale for further evaluation in patients with advanced cancer. The recommended dose of BAY 43-9006 (SORAFENIB) for future studies is 400 mg bid as a continuous dosing schedule.
研究概览
详细说明
This study propose to treat patients with metastatic and hormone-refractory prostatic cancer in first intention. There is no limits of age from 18 years old. A new inhibitor of angiogenesis (Sorafenib) is associated to the standard treatment in this type of pathology.
Patients have to demonstrate radiologically a disease progression and also a progression based on increase of psa level.
The main objective is to Determine the recommended dose of BAY 43-9006 in combination with docetaxel in hormone-refractory prostate cancer patients as first line treatment in patients with metastatic hormone-refractory prostate cancer.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Namur、比利时、5000
- Sainte Elisabeth
-
-
Brabant Wallon
-
Ottignies、Brabant Wallon、比利时、1340
- St Pierre
-
-
Brussels Capital
-
Brussels、Brussels Capital、比利时、1200
- Cliniques Universitaires St Luc
-
-
Hainaut
-
Charleroi、Hainaut、比利时、6000
- Notre Dame et Reine Fabiola
-
-
Namur
-
Yvoir、Namur、比利时、5030
- Clinique Universiataire de Mont Godinne
-
-
-
-
-
Paris、法国、75015
- Hopital Europeen Georges Pompidou
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Signed informed consent prior to beginning protocol specific procedures.
- 18 years
- Radiologically proven presence of metastases
- Histologically/cytologically proven prostate adenocarcinoma.
- Biochemically evaluable disease
Patients must have received prior hormonal therapy as defined below:
- Castration by orchiectomy and/or LHRH agonists with or without
- Antiandrogens
- Other hormonal agents (e.g., ketoconazole, ...)
- The testosterone level should be < 50 ng/dl (10) documented disease progression defined by PSA increase. Patients must have a value of at least 5 ng/ml in addition to increasing PSA to be eligible.
- Life expectancy > 3 months
- ECOG performance status 0-2.
- Normal cardiac function.
Exclusion Criteria:
- Prior chemotherapy except estramustine phosphate.
- Prior isotope therapy (e.g., strontium, samarium).
- Prior radiotherapy to >25% of bone marrow
- Prior therapy with anti-VEGF therapy
- Prior malignancy except the following: adequately treated basal cell or squamous cell skin cancer, or any other cancer from which the patient has been disease-free for >5 years.
- History or presence of central nervous system (CNS) disease (i.e. primary brain tumor, malignant seizures, CNS metastases or carcinomatous meningitis)
- Symptomatic peripheral neuropathy
- Other serious illness or medical condition the use of corticosteroids.
- Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening.
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BAY 9006.
- Major surgery with 4 weeks of study entry
- Autologous bone marrow transplant or stem cell rescue within 4 months of study entry
- Use of biologic response modifiers, such as G-CSF, within 3 weeks of study entry
- Treatment with any other anti-cancer therapy (except LHRH agonists) including any prescribed compounds and/or OTC products for the treatment of prostate cancer must be stopped.
- Treatment with drugs that are metabolized by the cytochrome P450 system (i.e warfarin sodium,…)
- Treatment with systemic corticosteroids used for reasons other than specified by the protocol must be stopped.
- Biphosphonates could not be initiated after inclusion into the protocol. At inclusion, patients receiving biphosphonates with a PSA progression could continue biphosphonates.
- Patients with reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial.
- Inadequate recovery from previous surgery, radiation, chemo-, biologic or immunotherapy
- Patients who have known hypersensitivity to the study medication
- Substance abuse, medical social, psychological conditions that may interfere with the subject's participation in the study or evaluation of study results
- Patients unable to sallow oral medications.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Determine the recommended dose of BAY 43-9006 (SORAFENIB) in combination with docetaxel in hormone-refractory prostate cancer patients as first line treatment in patients with metastatic hormone refractory prostate cancer.
大体时间:after the first 24 patients
|
after the first 24 patients
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Evaluation of pharmacokinetics and pharmacodynamics of BAY43-9006 in combination with docetaxel*
大体时间:after the first 24 patients
|
after the first 24 patients
|
Toxicity and safety
大体时间:at end of study
|
at end of study
|
Response rate in patients with measurable disease
大体时间:at end of study
|
at end of study
|
PSA response rate
大体时间:at end of study
|
at end of study
|
PSA response duration
大体时间:at end of study
|
at end of study
|
Time to PSA progression (=time between treatment start and PSA progression)
大体时间:at end of study
|
at end of study
|
Time to PSA progression after the last dose of docetaxel in patients with no progression after stopping docetaxel (= time between the last dose of docetaxel and PSA progression)
大体时间:at end of study
|
at end of study
|
Event progression-free survival
大体时间:at end of study
|
at end of study
|
合作者和调查者
调查人员
- 研究主任:Jean-Pascal H Machiels, Prof、Cliniques Universitaires St Luc -UCL
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.